[go: up one dir, main page]

SI2083811T1 - Postopki zdravljenja Downovega sindroma, sindroma krhkega X in avtizma - Google Patents

Postopki zdravljenja Downovega sindroma, sindroma krhkega X in avtizma

Info

Publication number
SI2083811T1
SI2083811T1 SI200731879T SI200731879T SI2083811T1 SI 2083811 T1 SI2083811 T1 SI 2083811T1 SI 200731879 T SI200731879 T SI 200731879T SI 200731879 T SI200731879 T SI 200731879T SI 2083811 T1 SI2083811 T1 SI 2083811T1
Authority
SI
Slovenia
Prior art keywords
syndrome
autism
fragile
methods
treating down
Prior art date
Application number
SI200731879T
Other languages
English (en)
Inventor
Randall L. Carpenter
Kathryn Roberts
Mark F. Bear
Original Assignee
Clinical Research Associates, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clinical Research Associates, Llc filed Critical Clinical Research Associates, Llc
Publication of SI2083811T1 publication Critical patent/SI2083811T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Heat Treatment Of Sheet Steel (AREA)
  • Surgical Instruments (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200731879T 2006-11-22 2007-11-21 Postopki zdravljenja Downovega sindroma, sindroma krhkega X in avtizma SI2083811T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86073306P 2006-11-22 2006-11-22
US156707P 2007-11-02 2007-11-02
PCT/US2007/024311 WO2008066750A1 (en) 2006-11-22 2007-11-21 Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
EP07862184.4A EP2083811B1 (en) 2006-11-22 2007-11-21 Methods of treating down's syndrome, fragile x syndrome and autism

Publications (1)

Publication Number Publication Date
SI2083811T1 true SI2083811T1 (sl) 2017-02-28

Family

ID=39272866

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200731879T SI2083811T1 (sl) 2006-11-22 2007-11-21 Postopki zdravljenja Downovega sindroma, sindroma krhkega X in avtizma

Country Status (16)

Country Link
US (6) US8143311B2 (sl)
EP (3) EP2567696A1 (sl)
JP (1) JP2010510314A (sl)
AU (1) AU2007325836B2 (sl)
CA (1) CA2670116C (sl)
CY (1) CY1118406T1 (sl)
DK (1) DK2083811T3 (sl)
ES (1) ES2610508T3 (sl)
HR (1) HRP20170027T1 (sl)
HU (1) HUE032743T2 (sl)
LT (1) LT2083811T (sl)
PL (1) PL2083811T3 (sl)
PT (1) PT2083811T (sl)
RS (1) RS55585B1 (sl)
SI (1) SI2083811T1 (sl)
WO (1) WO2008066750A1 (sl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2612115T3 (es) * 2008-12-08 2017-05-12 Biocodex Compuestos y métodos para tratar trastornos del espectro autista
EP2395990B1 (en) 2009-02-12 2015-01-07 Indiana University Research and Technology Corporation Material and methods for treating developmental disorders including comorbid and idiopathic autism
US8334287B2 (en) 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
WO2011053636A1 (en) * 2009-10-27 2011-05-05 Mount Sinai School Of Medicine Methods of treating psychiatric or neurological disorders with mglur antagonists
WO2011109398A2 (en) * 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20120016021A1 (en) * 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
US8946206B2 (en) 2010-12-17 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improving cognitive function
CA2874737A1 (en) 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Use of baclofen to treat insomnia
JP2016506380A (ja) * 2012-11-28 2016-03-03 ニューレン ファーマシューティカルズ リミテッド グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を使用する自閉症スペクトラム障害の処置
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014128882A1 (ja) * 2013-02-21 2014-08-28 医療法人 和楽会 不安うつ病の治療薬
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
DK3058371T3 (da) 2013-10-14 2021-08-02 Univ Indiana Res & Tech Corp Anvendelse af acamprosat til at modulere erk-1-2-aktivering i dyremodeller til fxs og asd og individer diagnosticeret med fxs og asd
WO2016115504A1 (en) 2015-01-15 2016-07-21 Allaysis, Llc Intravenous baclofen formulations and treatment methods
WO2016132217A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of improving gaba-b receptor agonist therapy
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
WO2017015049A1 (en) 2015-07-17 2017-01-26 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US20180042903A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10535243B2 (en) * 2016-10-28 2020-01-14 HBH Development LLC Target behavior monitoring system
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
AU2018309049A1 (en) 2017-08-04 2020-02-27 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of diabetes and related conditions
US20210057078A1 (en) * 2018-01-18 2021-02-25 Cureapp, Inc. System, device, method, and program for treating disorder treatable by behavior modification
CN111670050A (zh) 2018-01-30 2020-09-15 爱普宁公司(特拉华) 用于治疗睡眠呼吸暂停的方法和组合物
US10765666B2 (en) 2018-09-20 2020-09-08 Ovid Therapeutics Inc Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
US11186909B2 (en) * 2019-08-26 2021-11-30 Applied Materials, Inc. Methods of depositing low-K films
USD967184S1 (en) * 2021-02-26 2022-10-18 Oracle International Corporation Display screen or portion thereof with icon, or paper product with surface ornamentation
USD970544S1 (en) * 2021-02-26 2022-11-22 Oracle International Corporation Display screen or portion thereof with icon or paper product with surface ornamentation
USD1059370S1 (en) * 2021-09-15 2025-01-28 Capital Preferences NZ Limited Display screen or portion thereof with an animated graphical user interface for a sustainability simulator
US11523984B1 (en) 2021-11-12 2022-12-13 Amneal Pharmaceuticals Llc Compositions and methods of administering baclofen
WO2023178183A1 (en) * 2022-03-16 2023-09-21 University Of Florida Research Foundation, Incorporated Combinatorial activation of gaba(b) and alpha-2 adrenergic receptors for treatment of stress induced depression

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
GB1247067A (en) 1968-02-16 1971-09-22 Fujisawa Pharmaceutical Co Tricyclic enol ether compounds and the preparation thereof
FR2492258A1 (fr) 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4411901A (en) 1981-12-23 1983-10-25 Mead Johnson & Company Benzisothiazole and benzisoxazole piperazine derivatives
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
JPH0625181B2 (ja) 1985-03-27 1994-04-06 住友製薬株式会社 新規なイミド誘導体
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5021421A (en) 1989-03-03 1991-06-04 Dainippon Pharmaceutical Co., Ltd. 2-(1-Piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US6107025A (en) 1991-05-24 2000-08-22 Baylor College Of Medicine Diagnosis of the fragile X syndrome
US6180337B1 (en) 1991-05-24 2001-01-30 Baylor College Of Medicine Diagnosis of the fragile X syndrome
DE4243287A1 (de) 1992-06-19 1993-12-23 Basf Ag N-Substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung
DE4339702A1 (de) 1993-11-22 1995-05-24 Bayer Ag Verfahren zur Herstellung von harten Polyurethanschaumstoffen
DE69510928D1 (de) 1994-03-14 1999-08-26 Novo Nordisk As Heterocyclische verbindungen, ihre herstellung und verwendung
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1996015099A1 (en) 1994-11-09 1996-05-23 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
US6011021A (en) 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
JPH11509847A (ja) 1995-07-31 1999-08-31 ノボ ノルディスク アクティーゼルスカブ ヘテロ環式化合物、それらの調製及び使用
WO1997005137A1 (en) 1995-07-31 1997-02-13 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
GB9609976D0 (en) 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
US5795877A (en) 1996-12-31 1998-08-18 Guilford Pharmaceuticals Inc. Inhibitors of NAALADase enzyme activity
US5672592A (en) 1996-06-17 1997-09-30 Guilford Pharmaceuticals Inc. Certain phosphonomethyl-pentanedioic acid derivatives thereof
US6046180A (en) 1996-06-17 2000-04-04 Guilford Pharmaceuticals Inc. NAALADase inhibitors
US6025344A (en) 1996-06-17 2000-02-15 Guilford Pharmaceuticals Inc. Certain dioic acid derivatives useful as NAALADase inhibitors
US5863536A (en) 1996-12-31 1999-01-26 Guilford Pharmaceuticals Inc. Phosphoramidate derivatives
US5902817A (en) 1997-04-09 1999-05-11 Guilford Pharmaceuticals Inc. Certain sulfoxide and sulfone derivatives
WO1998006724A1 (fr) 1996-08-09 1998-02-19 Yamanouchi Pharmaceutical Co., Ltd. Agonistes du recepteur du glutamate metabotropique
FR2759366B1 (fr) 1997-02-11 1999-04-16 Centre Nat Rech Scient Composes constituant notamment des effecteurs de recepteurs du systeme nerveux central sensibles aux amino acides neuroexcitateurs, leur preparation et leurs applications biologiques
NZ337827A (en) 1997-04-07 2000-12-22 Lilly Co Eli Use of GluR5 receptor antagonists in the manufacture of medicaments for treating pain
EP0994707A4 (en) 1997-05-27 2001-11-14 Guilford Pharm Inc INHIBITORS OF NAALADASE ENZYME ACTIVITY
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
PL192029B1 (pl) 1997-08-14 2006-08-31 Hoffmann La Roche Zastosowanie heterocyklicznych eterów winylowych, nowe heterocykliczne etery winylowe, sposób ich wytwarzania i środek farmaceutyczny
CA2301599C (en) * 1997-08-25 2003-03-25 Neurogen Corporation Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
EP1037878A2 (en) 1997-11-21 2000-09-27 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
AU2642699A (en) 1998-03-03 1999-09-20 Yamanouchi Pharmaceutical Co., Ltd. Remedies for brain infarction
CN1367775A (zh) 1998-04-17 2002-09-04 肯尼思·柯里 用作亲代谢型谷氨酸受体对抗剂的立方烷衍生物及其制备方法
US20030216293A1 (en) 1998-07-07 2003-11-20 Tomas Eriksson Use of composition comprising at least one substance within the group GnRH-analogues for treatment of obsessive -compulsive disorder (OCD)
SE9802438L (sv) 1998-07-07 1999-07-19 Laekartjaenster I Vaestsverige Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom
DK1117403T3 (da) 1998-10-02 2004-04-13 Sibia Neurosciences Inc MGLUR5-antagonister til behandling af smerte og angst
GB9823845D0 (en) 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
GB9823847D0 (en) 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
TW593241B (en) 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
AU4797400A (en) 1999-05-17 2000-12-05 Eli Lilly And Company Metabotropic glutamate receptor antagonists
ES2249272T3 (es) 1999-06-02 2006-04-01 Nps Pharmaceuticals, Inc. Antagonistas de receptores de glutamato metabotropicos y su uso para el tratamiento de enfermedades del sistema nervioso central.
EP1194400A1 (en) 1999-06-30 2002-04-10 Prescient Neuropharma Inc. 2-aminoindane analogs
AU5667100A (en) 1999-07-02 2001-01-22 Prescient Neuropharma Inc. Novel aminoindanes
ES2198323T3 (es) 1999-07-06 2004-02-01 Eli Lilly And Company Profarmacos de diesteres de un acido decahidroisoquinolin-3-carboxilico.
EP1238069A2 (en) 1999-07-15 2002-09-11 McGill University Antisense oligonucleotides for metabotropic glutamate receptor type 1 (mglur1)
EP1205187A1 (en) 1999-08-02 2002-05-15 Yamanouchi Pharmaceutical Co. Ltd. Remedies for neurogenic pains
ATE254614T1 (de) 1999-08-06 2003-12-15 Hoffmann La Roche Tetrahydro-benzo(d)azepine und deren verwendung als metabotrope glutamatrezeptor-antagonisten
EP1202720A4 (en) * 1999-08-10 2004-02-25 Uab Research Foundation USE OF GABA AGONISTS TO TREAT SPASTIC, CONVULSIVE AND EPLEPSY DISORDERS
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
AU1071301A (en) 1999-11-01 2001-05-14 Eli Lilly And Company Pharmaceutical compounds
GB0005700D0 (en) 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
US20030008897A1 (en) 2000-03-17 2003-01-09 Mendel Carl M. Method of controlling weight gain associated with therapeutic drugs
US6455553B1 (en) * 2000-10-03 2002-09-24 Albert Einstein College Of Medicine Of Yeshiva University Method for treating a demyelinating condition
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
CA2442478C (en) 2001-04-02 2010-02-02 Mark F. Bear Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
US6831077B2 (en) 2002-07-25 2004-12-14 Comprehensive Neuroscience, Inc. Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation
US6656172B1 (en) * 2002-09-27 2003-12-02 Medtronic, Inc. Method for treating severe tinnitus
CA2529318C (en) 2003-06-24 2013-09-17 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
AU2004267100B2 (en) * 2003-08-20 2010-10-07 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
WO2006012403A1 (en) * 2004-07-20 2006-02-02 Massachusetts Institute Of Technology Methods of treatment: cell signaling and glutamate release
US20060058271A1 (en) 2004-09-16 2006-03-16 Geier Mark R Methods for screening, studying, and treating dissorders with a component of mercurial toxicity
US20070254314A1 (en) 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
US9095713B2 (en) * 2004-12-21 2015-08-04 Allison M. Foster Methods and systems for treating autism by decreasing neural activity within the brain
US20060264381A1 (en) * 2005-05-05 2006-11-23 Bear Mark F Methods of treating obsessive compulsive disorder
WO2007029063A2 (en) * 2005-07-29 2007-03-15 Ecole Polytechnique Federale De Lausanne (Epfl) Treatment and/or prevention of pervasive developmental disorders
US20080312279A1 (en) * 2005-10-26 2008-12-18 Warren Stephen T Compositions for Treating Fragile X and Other Disorders Methods of Use Thereof, and Screening for Compounds for Fragile X and Other Disorders
WO2007053596A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20070191440A1 (en) * 2006-01-25 2007-08-16 Solomon Michael E Methods of treating autism and fragile X syndrome
WO2011056849A1 (en) 2009-11-05 2011-05-12 Massachusetts Institute Of Technology Methods of treating elevations in mtor signaling

Also Published As

Publication number Publication date
US20120122986A1 (en) 2012-05-17
JP2010510314A (ja) 2010-04-02
US8143311B2 (en) 2012-03-27
US20130012586A1 (en) 2013-01-10
US20130261186A1 (en) 2013-10-03
AU2007325836A1 (en) 2008-06-05
LT2083811T (lt) 2017-01-25
PL2083811T3 (pl) 2017-05-31
ES2610508T3 (es) 2017-04-27
US9044443B2 (en) 2015-06-02
EP2083811B1 (en) 2016-10-26
HUE032743T2 (en) 2017-10-30
US20120129940A1 (en) 2012-05-24
EP2083811A1 (en) 2009-08-05
US8273715B2 (en) 2012-09-25
PT2083811T (pt) 2017-01-23
AU2007325836B2 (en) 2011-07-21
CY1118406T1 (el) 2017-06-28
RS55585B1 (sr) 2017-06-30
CA2670116C (en) 2015-03-10
US8278276B2 (en) 2012-10-02
EP2578216A1 (en) 2013-04-10
US20100029770A1 (en) 2010-02-04
HRP20170027T1 (hr) 2017-03-10
EP2567696A1 (en) 2013-03-13
DK2083811T3 (en) 2017-01-30
US20130012587A1 (en) 2013-01-10
CA2670116A1 (en) 2008-06-05
WO2008066750A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
RS55585B1 (sr) Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma
GB2434604B (en) Porous composites containing hydrocarbon-soluble well treatment agents and methods for using the same
EP1951263A4 (en) MULTITARGETING DISTURBING RNAS WITH TWO ACTIVE STRANDS AND DESIGN AND APPLICATION METHODS
IL183963A0 (en) 1 - aminocyclohexane - derivatives for the treatment of multiple sclerosis, emotional liability and pseudobulbar affect
EG26217A (en) Activated carbon impregnated with acid and a way to form
EP2078051A4 (en) PROCESS FOR PRODUCTION OF POLYSILOXANES AND USE THEREOF
SI2079760T1 (sl) Sestavki in metode za zdravljenje okužb
ZA200704677B (en) Compositions and methods for the treatment of autism
EP1845915A4 (en) SYSTEMS AND METHOD FOR TARGET HEAT TREATMENT
EP2012972A4 (en) ABRASIVE ARTICLE STRUCTURE AND METHOD OF MANUFACTURING AND USING THE SAME
EP1931601A4 (en) DENITRIFICATION PROCESS AND SYSTEM
ZA200709727B (en) Compounds and methods for the treatment of prevention of flavivirus infections
ZA200807747B (en) Catalyst and hydrotreting process
EP2098200A4 (en) ABSORBENT ARTICLE AND ITS MANUFACTURING PROCESS
IL195272A0 (en) Methods and compositions for the treatment of viral infections
EP1912723A4 (en) GASQUENCY AND LAUNDRY EXTRACTION SYSTEM
GB2442535B (en) Method and articles
IL188728A0 (en) Methods of treating epileptogenesis
ZA200805224B (en) Geopolymeric particles, fibers, shaped articles and methods of manufacture
HU0600668D0 (en) Active carrier, process for producing thereof and the use of thereof
TWI369732B (en) Semiconductor process and chamber used
EP1905861A4 (en) PROCESS FOR FORMING ALUMINUM COATING FILM, ALUMINUM FIBER, AND GAS PROCESSING SYSTEM COMPRISING ALUMINUM FIBER
GB2435262B (en) Method, composition and articles
EP2085061A4 (en) METHOD OF MANUFACTURING ABSORBENT ARTICLE AND ABSORBENT ARTICLE
EP1846139A4 (en) GAS TREATMENT ADSORPTION-OXIDATION SYSTEM